The pso Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the pso Hub cannot guarantee the accuracy of translated content. The pso and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View pso content recommended for you
Laura CoatesDuring the European Alliance of Associations for Rheumatology (EULAR) 2022 Congress, the Psoriasis and Psoriatic Arthritis Hub was pleased to speak to Laura Coates, University of Oxford, Oxford, UK. We asked, What’s new in psoriatic arthritis (PsA) at EULAR 2022?
What’s new in PsA at EULAR 2022?
Coates summarized safety and outcome data from several studies that were presented at EULAR, including the COMPLETE-PsA study, as well as two studies that investigated bimekizumab. In addition, Coates discusses potential considerations when deciding which patients are suitable for treatment with a JAK inhibitor.